Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Oncopeptides AB ( (SE:ONCO) ).
Oncopeptides reported strong commercial momentum in 2025, with full-year net sales rising 125 percent to SEK 71.1 million and fourth-quarter sales up 88 percent to SEK 18.6 million, driven by robust demand for Pepaxti, particularly in Italy. Despite this growth, the company remains loss-making with an operating loss of SEK 61.5 million in Q4 and cash of SEK 82.3 million at year-end, and it now expects to reach positive cash flow in 2027 instead of earlier plans.
Management is sharpening the company’s focus by streamlining German operations to reach profitability there in 2026, reallocating resources from internal preclinical research toward clinical development, and increasingly relying on external collaborations for its PDC and SPiKE platforms. A key strategic move is the planned clinical push into glioblastoma, leveraging its PDC technology to cross the blood-brain barrier, alongside ongoing negotiations with a major Japanese pharma partner and a rights issue of up to SEK 200 million to fund Pepaxti commercialization and advance the glioblastoma program into the clinic.
The company highlights growing medical validation for Pepaxti, with more than 600 patients treated since EMA approval and inclusion in major European myeloma treatment guidelines. This strengthening clinical and commercial footprint in multiple myeloma, combined with pipeline expansion into high-unmet-need indications like glioblastoma, is intended to evolve Oncopeptides from a niche late-stage myeloma player into a broader oncology innovator, with 2026 positioned as a pivotal year for operational focus and pipeline progress.
The most recent analyst rating on (SE:ONCO) stock is a Hold with a SEK3.00 price target. To see the full list of analyst forecasts on Oncopeptides AB stock, see the SE:ONCO Stock Forecast page.
More about Oncopeptides AB
Oncopeptides AB is a Swedish biopharmaceutical company focused on developing cancer therapies, with a core emphasis on its peptide-drug conjugate (PDC) platform. Its main commercial product is Pepaxti, a treatment for triple-class refractory multiple myeloma that is being commercialized in Europe, while the company explores expansion into additional indications and geographies, including Japan and new brain cancer therapies.
Average Trading Volume: 1,772,794
Technical Sentiment Signal: Sell
Current Market Cap: SEK722.7M
For an in-depth examination of ONCO stock, go to TipRanks’ Overview page.